<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230825059253N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-03</date_registration>
      <primary_sponsor>Research assistant of Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>The effect of reducing the size of the intubation tube on the amount of sore throat after surgery</public_title>
      <acronym></acronym>
      <scientific_title>comparing the use of tracheal tube size 7.5 and 6.5 in men and 7 and 6 in women during laparoscopic surgery in terms of reducing the incidence of sore throat and hoarseness after intubation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>140</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72352</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, randomization is done based on the last digit of the file number, and in patients with an even file number, a larger tube size is used, and in patients with an odd file number, a smaller tube size is used, Blinding description: In this study, only the study participants are unaware of the size of the tube used, and due to the fact that the variable is the size of the tube, there is no possibility of blinding the clinical caregiver.</study_design>
      <phase>3</phase>
      <hc_freetext>Sore throat after surgery.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group consists of men who meet the conditions for entering the study, for whom we place an endotracheal tube number 6.5, which are compared with the control group of men who are placed with an endotracheal tube number 7.5. Intervention 2: Intervention group: The second intervention group includes women who meet the conditions for entering the study, for whom we place an endotracheal tube number 6, which are compared with the control group of women who are placed with an endotracheal tube number 7. Intervention 3: Control group: The first control group of men with conditions for entering the study, for whom we place an endotracheal tube No. 7.5, which are compared to the first intervention group for which we place an endotracheal tube No. 6.5. Intervention 4: Control group: The second control group of women with conditions to enter the study, for whom we place an endotracheal tube number 7, which are compared to the second intervention group for which we place an endotracheal tube number 6.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data will be published in the form of a research plan after deidentifying the individuals, which includes all the variables and outcomes of the study.

When:
After collecting the data and analyzing the statistics, which is about the year 1403, it will be published in the form of a research project.

To whom:
The data is accessible to all people, including researchers, institutions, universities, and industrial companies

Conditions:
The information and results of the study and data are accessible to other researchers on the condition of mentioning the source of the information and data

Where to obtain:
In order to receive the data, one should be in contact with the direct manager of the project, Mr. Dr. Pouria Namei, with the email address namaeip4001@mums.ac.ir, and if there are necessary conditions, the information will be provided to the people.

How to obtain:
If there is a request, an official letter of request and conditions should be sent to the email address namaeip4001@mums.ac.ir. If the necessary conditions are met, correspondence will be done with the person or institution within a week through this email to send the data.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Pooria Namaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kaveh Blvd., Anuri St., Anuri 2, No. 20</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177795915</zip>
        <telephone>+98 51 3840 2776</telephone>
        <email>namaeip@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Masoume Tabari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mashhad University of Medical Sciences</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913131</zip>
        <telephone>+98 51 3843 3999</telephone>
        <email>tabarim@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>18-60 years old candidates for laparoscopic surgery
BMI below 35
ASA I or II clinical status.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>history of allergies and respiratory diseases
history of respiratory infection during the last month
History of cold or respiratory infection in the last month
History of esophageal reflux
Patients who fall into four Cormak-Lehane classifications during laryngoscopy
Any disturbance in hemodynamics or oxygen delivery to the patient during anesthesia
Need more than two laryngoscopy directions for intubation Even in patients with a BMI below 35, if re-intubation is needed due to the need to replace the tracheal tube due to overinflation
Patients whose surgery lasts more than 3 hours</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J04.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute laryngitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group consists of men who meet the conditions for entering the study, for whom we place an endotracheal tube number 6.5, which are compared with the control group of men who are placed with an endotracheal tube number 7.5.</i_keyword>
      <i_keyword>Intervention group: The second intervention group includes women who meet the conditions for entering the study, for whom we place an endotracheal tube number 6, which are compared with the control group of women who are placed with an endotracheal tube number 7.</i_keyword>
      <i_keyword>Control group: The first control group of men with conditions for entering the study, for whom we place an endotracheal tube No. 7.5, which are compared to the first intervention group for which we place an endotracheal tube No. 6.5.</i_keyword>
      <i_keyword>Control group: The second control group of women with conditions to enter the study, for whom we place an endotracheal tube number 7, which are compared to the second intervention group for which we place an endotracheal tube number 6.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Evaluation of postoperative sore throat and voice severity (according to the patient's statement). Timepoint: at 1, 6, and 24 hours after surgery. Method of measurement: based on VAS criteria.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-24</approval_date>
        <contact_name>Educational, Research and Treatment Center of Imam Reza Hospital - Mashhad University of Medical Sci</contact_name>
        <contact_address>No. 20, Shahid Kaveh St., Malek Shaara St., Anuri St., 2 Anuri St mashhsd Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
